Corona Remedies Ltd Q3 FY26 Earnings Analysis

- CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM). - PAT (Profit After Tax) growth expectation is high-teens to 20% annually. - Volume growth contributes approximately 5% to overall growth, supported by new product introductions. - The company plans to launch 8 to 10 new products yearly, primarily organically (95%), with a few acquisitions (5-7%). - Expansion includes entry into new therapies like infertility, rheumatology, and spine. - Growth is driven by chronic and semi-chronic segments, constituting around 70-72% of revenue. - Increasing market share through specialist and super-specialist prescribers is a key focus. - International business growth is gradual, expected to increase from 3-4% to 7-9% in coming years. - Manufacturing capacity expansion (e.g., 600 kg line) to support volume growth; new plant planned for FY'28-FY'29.

- CORONA Remedies targets consistent mid-teen revenue growth (~15%) and high-teen PAT growth (~20%) annually. - The company aims for sustained EBITDA margin improvement, currently at ~24%, with potential to reach high 20s to ~30% in medium to long term as employee costs normalize. - EPS growth is expected to align with PAT growth of around 20% year-on-year. - Growth drivers include organic expansions (new product launches, including 8-10 new products yearly), specialist and super-specialist therapy focus, and selective inorganic brand acquisitions. - Manufacturing capacity expansion planned by FY'28-'29 to support growth. - International business expected to grow steadily, maintaining about 10% of overall revenue long term. - Overall guidance is to maintain a balance of strong top-line and profitability growth for superior shareholder returns.

- Recently capitalized a 600 kg manufacturing line, unlocking 40% capacity. - Planning to consider adding a new manufacturing block around FY'28-'29 to support future growth. - Currently, no immediate need to add new lines such as injectable or biosimilar lines; will evaluate at the appropriate time. - Maintain a balanced mix of 65% in-house manufacturing and 35% CDMO/CMO outsourcing. - No significant incremental investment planned currently for international market growth; internal cash generation sufficient. - Continuous evaluation of acquisitions and in-licensing opportunities, with two brand acquisitions currently under evaluation, though nothing concrete yet.

- Currently, CORONA Remedies Limited does not have any plans for new fundraising through debt or equity. - The company is net cash positive with over Rs. 100 crore in net cash. - Internal cash generation and strong operating cash flow (84% OCF to EBITDA conversion) are sufficient to fund growth initiatives. - For manufacturing capacity expansion, the company plans to start considering a new plant around FY'28-FY'29, but no immediate capital raising is planned. - Any incremental investments required to drive export growth or other expansions will be funded through internal accruals and cash flows, not through external debt or equity.

The transcript provided does not explicitly mention details about the current or expected order book or pending orders for CORONA Remedies Limited. However, from the discussion, the following points related to order flow and growth can be inferred: - CORONA Remedies is focusing on organic growth with 15% revenue growth guidance. - The company has recently launched and is launching new products including those from the Bayer portfolio, biosimilars, and GLP-1 injectable by March 2026. - The company is expanding capacities, including unlocking 40% capacity by the 600 kg manufacturing line. - Plans for additional plant expansion are being considered for FY'28-FY'29 to support growth. - They maintain a strong focus on chronic and semi-chronic segments, with a broad portfolio of 70+ brands. - No specific mention of order book size or pending orders was made during the call. If you need detailed order book figures, it may be better to reach out directly to their Investor Relations.